NCT06791681
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
- Tongji Hospital, Tongji Medical College Wuhan, Hubei, China
Clinical trial condition
Relapsed/ Refractory Multiple Myeloma
Explore clinical trials studying Relapsed/ Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.
2 public trials
1 recruiting study
Relapsed/ Refractory Multiple Myeloma trial results
Active, Not Recruiting
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
NCT05338775
- Conditions
- Relapsed/ Refractory Multiple Myeloma
- Locations
-
- Colorado Blood Cancer Institute Denver, Colorado, United States
- The Blavatnik Family Chelsea Medical Center at Mount Sinai New York, United States
- Icahn School of Medicine at Mount Sinai New York, United States
- Memorial Sloan Kettering Cancer Center New York, United States